Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

EBUS-TBNA guides need for further treatment in RCC

Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.

Key clinical point: Minimally invasive cytology sampling of mediastinal lymph nodes using endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is useful for evaluation of mediastinal lymphadenopathy and determining the need for further treatment in patients with a previous diagnosis of renal cell carcinoma (RCC).

Major finding: Sixteen patients (15 males, mean age 59 years, range 44–81 years) were diagnosed by cytological and cell block study to have metastatic clear cell RCC. Twelve patients had been diagnosed with clear cell RCC in the past (mean 39 months, range 4–89 months) while in four, the tumor was primarily diagnosed in the staging phase on the basis of EBUS-TBNA. The EBUS features of the mediastinal nodal masses included increase of size (mean 2.5 cm, range 1.6–3.8 cm), irregular, inhomogeneous, hypervascular, and hyperechoic echotexture.

Study details: Examination of 1744 EBUS-TBNA studies of mediastinal and hilar lymph nodes performed for a variety of clinical indications including mediastinal malignancy.

Disclosures: The authors had no relevant financial disclosures.

Source: Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.

Citation:

Val-Bernal J et al. Pathology Research and Practice 2018; 214 (7), 949-56.

This Week's Must Reads

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Must Reads in Renal Cell Carcinoma

In mRCC: Sunitinib alone not inferior to nephrectomy-sunitinib, Méjean A et al. N Engl J Med. 2018 Aug 2. doi: 10.1056/NEJMoa1803675.

Proactive management eases side effects of sunitinib treatment in RCC, Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329

Red cell distribution width might predict cancer-specific survival in RCC , Życzkowski M et al. Clinical Genitourinary Cancer 2018 June (16), e677-e683. https://doi.org/10.1016/j.clgc.2017.12.003

mRCC: Patients survive longer at high-volume centers, Joshi SS et al. Euro Urol. 2018 Sep;74[3]:387-93.

High PD1 mRNA levels tied to anti-PD1 monotherapy response, Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.